Vascular effects of dietary L-arginine supplementation

Atherosclerosis

Volumn 162, Issue 1, 2002, Pages 1-15

  Preli, Robert B ^a   Klein, Karen Potvin ^a   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical studies; Hypercholesterolemic animals; L arginine; Vascular endothelium

Indexed keywords

ARGININE; CELL ADHESION MOLECULE; NITRIC OXIDE;

ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD VESSEL INJURY; CARDIOVASCULAR SYSTEM; CELL ADHESION; CELL FUNCTION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFECT; ENDOTHELIUM; EXERCISE TOLERANCE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LEUKOCYTE FUNCTION; LIMB ISCHEMIA; MACROPHAGE; META ANALYSIS; MONOCYTE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SAMPLING; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TIME; VASCULAR RING; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; ARGININE; CELL ADHESION; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DIETARY SUPPLEMENTS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PLATELET AGGREGATION; TREATMENT OUTCOME; VASODILATION;

EID: 0036230436     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00717-1     Document Type: Review

References (61)

1. Coronary stenosis dilatation induced by L-arginine
2. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
3. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension
4. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors
5. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease
6. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris
7. Derangements of the nitric oxide synthase pathway, L-arginine and cardiovascular diseases
8. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator
9. Atherosclerosis and the two faces of endothelial nitric oxide synthase
10. The L-arginine-nitric oxide pathway
11. The biological and pharmacological role of nitric oxide in platelet function
12. Nitric oxide: An endogenous modulator of leukocyte adhesion
13. Nitric oxide: Physiology, pathophysiology and pharmacology
14. Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases
15. The L-arginine: Nitric oxide pathway
16. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
17. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox
18. The clinical pharmacology of L-arginine
19. Cellular and molecular mechanisms of endothelial cell dysfunction
20. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells
21. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice
22. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit
23. Discordant effects of dietary L-arginine on vascular structure and reactivity in hypercholesterolemic rabbits
24. Supplementation of hypercholesterolemic rabbits with L-arginine reduces vascular release of superoxide anions and restores NO production
25. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin
26. Dietary L-arginine and α-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms
27. Dietary arginine prevents atherogenesis in the coronary artery of hypercholesterolemic rabbits
28. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits
29. Control of accelerated vein graft atheroma with the nitric oxide precursor L-arginine
30. L-arginine supplementation improves venous endothelial cell but not smooth muscle cell dysfunction induced by prolonged diet-induced hypercholesterolemia
31. Combination therapy of cholesterol reduction and L-arginine supplementation controls accelerated vein graft atheroma
32. Chronic dietary L-arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits
33. Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke
34. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilation in the hypercholesterolemic rabbit: Response according to treatment duration, anatomic site, and sex
35. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury
36. L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty
37. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits
38. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: Effects on neointimal hyperplasia and vascular remodeling
39. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine
40. L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix
41. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbits: Inhibition with L-arginine
42. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits
43. L-arginine decreases blood pressure and left ventricular hypertrophy in rats with experimental aortic coarctation
44. Arginine needs, physiological state and unusual diets: A re-evaluation
45. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men
46. Oral L-arginine improves endothelium-dependent dilation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease
47. Oral L-arginine improves endothelium-dependent dilation of hypercholesterolemic young adults
48. Correction of endothelial dysfunction in chronic heart failure: Additional effects of exercise training and oral L-arginine supplementation
49. Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women
50. Oral L-arginine in patients with coronary artery disease on medical management
51. Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels
52. Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries in patients with severe heart failure
53. Long-term L-arginine supplementation improves small vessel coronary endothelial function in humans
54. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: Reversibility with L-arginine but not vitamin C
55. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans
56. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine
57. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans
58. Effects of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris
59. Nutritional therapy for peripheral disease: A double-blind, placebo-controlled, randomized trial of HeartBar
60. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure
61. Arginine intake and risk of coronary heart disease mortality in elderly men